Role of Non-Coding RNAs in the Progression of Liver Cancer: Evidence from Experimental Models by O’Brien, April et al.
cancers
Review
Role of Non-Coding RNAs in the Progression of Liver
Cancer: Evidence from Experimental Models
April O’Brien 1, Tianhao Zhou 1, Christopher Tan 2, Gianfranco Alpini 3,4 and Shannon Glaser 1,*
1 Department of Medical Physiology, College of Medicine, Texas A&M University, Bryan, TX 77807, USA;
aprilobrien@tamu.edu (A.O.); tianhaozhou@tamu.edu (T.Z.)
2 Baylor Scott and White Health, Temple, TX 76508, USA; christopher.tan@bswhealth.org
3 Richard L. Roudebush VA Medical Center, Indiana University School of Medicine,
Indianapolis, IN 47405, USA; galpini@iu.edu
4 Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of
Medicine, Indianapolis, IN 47405, USA
* Correspondence: sglaser@tamu.edu
Received: 3 October 2019; Accepted: 21 October 2019; Published: 25 October 2019


Abstract: Liver cancer is a devastating cancer that ranges from relatively rare (around 2% of all cancers
in the United States) to commonplace (up to 50% of cancers in underdeveloped countries). Depending
upon the stage of pathogenesis, prognosis, or functional liver tissue present, transplantation or partial
hepatectomy may be the only available treatment option. However, due to the rise in metabolic
syndrome and the increasing demand for livers, patients often wait months or years for available
organs. Due to this shortage, doctors must have other treatment options available. One promising
area of cancer research lies in understanding the role of regulatory non-coding RNAs (ncRNAs) as
oncogenic drivers and potential targets for prospective therapies. While the role of these ncRNAs
was not initially clear, many of them have since been recognized to function as important players in
the regulation of gene expression, epigenetic modification, and signal transduction in both normal
and cancer cell cycles. Dysregulation of these different ncRNA subtypes has been implicated in the
pathogenesis and progression of many major cancers including hepatocellular carcinoma. This review
summarizes current findings on the roles noncoding RNAs play in the progression of liver cancer
and the various animal models used in current research to elucidate those data.
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1. Introduction
miRNAs, first discovered in 1993 by Lee and colleagues in the nematode Caenorhabditis elegans [1],
are a category of ncRNAs that are 19–22nt in length and that function primarily by mediating post
transcriptional gene silencing. Lee et al. initially found that in the nematode Caenorhabditis elegans,
the downregulation of the protein LIN-14 was essential in the progression from the nematode’s first
larval stage [2]. Downregulation of LIN-14 is dependent on the transcription of a second gene, LIN-4.
It was later discovered that the transcriptional products of LIN-4 had antisense complementarity to
multiple sites in the 3′ untranslatable region (3′ UTR) of LIN-14 mRNA [2,3]. The binding between
these complementary regions decreased LIN-14 protein expression, which allowed for the progression
of C. elegans development. In summary, miRNAs are transcribed in the nucleus and form distinctive
hairpin structures that can bind to their complementary messenger RNA targets in the cytoplasm. This
usually happened at their 3′-untranslatable regions (3′ UTRs) or open reading frames, blocking the
translation of proteins [4].
Small interfering RNAs of 21–23 nt also fall within the small noncoding RNA class. While they
differ in their origin from miRNAs, they are similar in both size and function. Additionally, mi- and
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siRNAs share the Dicer and Ago family of proteins to release them from the precursor forms and
participate in their silencing response. One notable difference between these similar RNA classes are
their origins; siRNAs are often derived from the environment and can be thought of as defenders of
the genome. Once a part of the RNA-induced silencing complex, or RISC complex, these siRNAs will
guide the RISC to their complementary targets for degradation [5].
Another small ncRNA is the piRNA (PIWI interacting) class, commonly referred to as PIWI RNAs.
These 23–36 nt long ncRNAs were first discovered by Aravin et al. [6] during the profiling of small RNAs
during Drosophila development. First described as repeat-associated siRNAs, they were eventually
named for their ability to form complexes with the P-element Induced Wimpy (PIWI) proteins of the
Argonaute family, where they fit into specific binding pockets and serve as guides to lead the Argonaute
protein to its target mRNA [7]. After their initial discovery in Drosophila, piRNA classes were found to
be abundantly present in the gonads of various vertebrates and invertebrates [8], and were determined
to play a key role in the suppression of transposon activity during germ line development [9]. However,
growing evidence suggests that the piRNA pathway genes extend into somatic cells as well [10].
In germ cells, the synthesis of piRNAs occurs in an electron-dense perinuclear area of the cell, whereas
in somatic cells, the processing of these molecules occurs in the outer membrane of the mitochondria [1].
The majority of these piRNAs exist as cluster loci that can be found in intergenic and genic regions [11].
There are three types of piRNA clusters: unistrand, dual strand and bidirectional. The unistrand
cluster is the source of piRNAs that are generated from a single DNA strand. The dual strand cluster is
the source that is generated from both DNA strands at a single gene location. Lastly, the bidirectional
cluster generates piRNAs from both DNA strands, but transcription of these molecules occurs in
opposite directions [1].
Somewhere between the classification of small and long noncoding RNA lies a unique set of RNA
known as small nucleolar RNA. Despite their name, snoRNAs range in size from 60–120 nt C/D box
snoRNAs to the larger (up to 300 nt) H/ACA box snoRNAs. Similarly to their smaller counterparts,
snoRNA complexes have been found to be associated with the Argonaute family of proteins [12].
snoRNAs are best known for their role in the guided methylation of RNAs, but other novel roles for
them have been described, such as functioning as miRNA post-modification [13].
The remainder of the ncRNAs are longer than 200 nt and are classified as long non-coding RNAs
(lncRNA) [14]. As of 2015, advancements in microarray and gene sequencing have allowed for the
identification of 58,648 lncRNA [15]. Like mRNAs, most lncRNAs are transcribed by RNA polymerase
II. It has also been found that these transcripts are able to be spliced, polyadenylated, and capped much
like mRNAs, but they do not code for any protein [16]. lncRNAs are classified into five types based on
their genomic location: sense, antisense, bidirectional, intronic, and intergenic. Sense lncRNAs overlap
with the sense strand of a protein coding gene. Antisense lncRNA overlap with the antisense strand of
a protein coding gene. When the sequence is oriented head to head with a protein coding gene, this is
referred to as bidirectional. Intronic sequences are located inside the intron of a protein coding gene.
Lastly, intergenic sequences are found in a region between two protein coding genes [1]. The functions
of lncRNA are broad. They have been shown to play roles in the regulation of transcription, mRNA
translation, nuclear structure organization, and certain protein activities [1]. There are several different
mechanisms by which lncRNAs regulate the transcriptional process. It has been shown that they can
directly interfere with promoter sequences [17] on their own, or do so by demethylating the promoter
genes [18]. lncRNAs may also serve as coactivators of certain transcription factors [19] or block the
binding of transcription factors to DNA [20]. While the various noncoding RNAs play unique roles in
organisms’ development and function, their roles in cancer progression often overlap with individual
members of the same RNA class, stimulating opposing pathways (Table 1).
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Table 1. Summary of noncoding RNAs and the corresponding experimental animal models.
Animal Model Type Noncoding RNA References
Xenograft
Nude
microRNA [21–24]
small interfering RNA [25]
small nucleolar RNA [26,27]
SCID microRNA [28,29]
NOC-SCID long noncoding RNA [30,31]
Chemical
DEN
microRNA [32–36]
small interfering RNA [37,38]
long noncoding RNA [39]
CCl4
microRNA [35,40,41]
small interfering RNA [37]
long noncoding RNA [42–44]
PIWI RNA [45]
Genetically Modified
HBx microRNA [46–49]
HBsAg microRNA [46]
MDR
microRNA [50–52]
long noncoding RNA [53,54]
Other
Tet-o-myc microRNA [55]
miR122 KO microRNA [56,57]
miR148a deficient microRNA [36]
KLF+/+, +/− small interfering RNA [37]
Malat1 KO small interfering RNA [38]
HCV-infected microRNA [58]
miRNA nanoparticles microRNA [59]
PH mouse PIWI RNA [45]
PH bamboo shark PIWI RNA [60]
2. MicroRNAs
MicroRNAs (miRNAs) have been identified as a valuable source of biomarkers for a wide range
of pathological conditions across many organs, including liver cancer. Within the human genome,
there may be an excess of 2000 mature miRNAs, which can regulate at least one-third of all human
protein-coding genes [61,62]. MiRNAs are small noncoding RNAs (18–22 nucleotides) that regulate
post-transcriptional gene expression through their binding to complementary 3′ untranslated regions
(3′-UTRs) of their messenger RNA (mRNA) targets [63]. The biogenesis of miRNAs takes place via a
multistep process. Primary miRNA (pri-miRNA) structures are initially transcribed in the nucleus
by RNA polymerase II. These precursor structures are subsequently cleaved into pre-miRNAs by the
DGCR8–Dorsha complex and translocated to the cytoplasm by Exportin 5 [64]. The pre-miRNAs are
then processed into duplex RNAs (about 22 nucleotides) by the endoribonuclease Dicer, and mature
single-strand miRNAs are produced by association with the RNA-inducing silencing complex (RISC).
Within the RISC, mature miRNAs can bind to target mRNAs and repress the translation of mRNAs
into proteins by preventing their translation and mRNA degradation [65,66]. Deregulation of miRNA
biogenesis is commonly observed in liver cancer. Profiling studies from different groups have reached
similar conclusions that miRNA expression can be distinguished between liver cancer patients and
normal healthy individuals [67–69]. Interestingly, dysregulated miRNAs can have different functional
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roles in cancer development through various cellular mechanisms such as cell proliferation, cell cycle
regulation, cell migration and invasion, apoptosis, etc. (Figure 1A). While some miRNAs promote
carcinogenesis by downregulation of tumor suppressor genes or activation of oncogenes, some miRNAs
have been implicated to do the opposite [21].Cancers 2019, 11, x 5 of 16 
 
 
Figure 1. Noncoding RNAs and their roles in liver cancer elucidated through various animal models. 
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methylation. Conversely, microRNAs play a role in decreased proliferation, migration, and 
angiogenesis, and increased apoptosis. (B) Small interfering RNAs target messenger RNA and silence 
their transcription. (C) The role of long noncoding RNA (lncRNA) varies with increased transcription, 
inflammation, resistance to chemotherapeutics, and fibrosis. In addition to increased HSC activation, 
there are higher incidence of mortality and cancer recurrence. Other lncRNAs have also been 
indicated in decreased tumorigenesis. (D) PIWI RNA have been shown to activate HSCs and increase 
TGF-1 expression and liver regeneration, in addition to regulating immune processes and 
development. (E) Small nucleolar RNAs provide resistance to chemotherapeutic drugs and have been 
shown to increase tumor size and weight. 
2.2. Chemical-Based Models 
Diethylnitrosamine (DEN) is a carcinogenic compound which is frequently used to 
experimentally induce liver fibrosis and/or HCC in animals. The incidence of DEN-induced HCC is 
determined, at least in part, by the strain. C3H and B6C3F1 mice are more likely to develop HCC 
compared to C57BL mice [47]. Recent studies have demonstrated miR-221 to be an oncogenic miRNA 
which plays an important role in the progression of HCC. For example, miR-221 overexpression is 
associated with sorafenib resistance in a DEN-induced HCC rat model, presumably by modulating 
caspase 3 expression and cellular apoptosis [48]. In another study, treatment with an antisense 2-O-
methyl oligoribonucleotide targeting miR-221 reduced tumor growth in miR-221tg-DEN-induced 
HCC mouse models [49]. In addition, Wu et al. explored the concurrent increase of liver progenitor 
cells (LPCs) and transforming growth factor-β (TGF-β) in DEN-induced rat hepatocarcinogenesis. 
They demonstrated that TGF-β-induced Akt activation and LPC transformation was mediated by 
miR-216a-modulated PTEN suppression [50]. 
Carbon tetrachloride (CCl4) is another hepatotoxin widely used to induce hepatocarcinogenesis 
in rodent animals.  In a study with 14 week CCl4 treatment, anti-miR-221 oligonucleotides or miR-
199a-3p mimics prevented HCC progression through the control of multiple cancer-associated 
molecular pathways, which included PI3K–AKT, WNT-β-catenin, cell cycle, invasion, and motility. 
Figure 1. Noncoding RNAs and their roles in liver cancer elucidated through various animal
models. (A) microRNAs regulate cancer progression through increasing stemness, drug resistance,
and DNA methylation. Conversely, microRNAs play a role in decreased proliferation, migration,
and angiogenesis, and increased apoptosis. (B) Small interfering RNAs target messenger RNA and
silence their transcription. (C) The role of long noncoding RNA (lncRNA) varies with increased
transcription, inflammation, resistance to chemotherapeutics, and fibrosis. In addition to increased
HSC activation, there are higher incidence of mortality and cancer recurrence. Other lncRNAs have
also been indicated in decreased tumorigenesis. (D) PIWI RNA have been shown to activate HSCs and
increase TGF-β1 expression and liver regeneration, in addition to regulating immune processes and
development. (E) Small nucleolar RNAs provide resistance to chemotherapeutic drugs and have been
shown to increase tumor size and weight.
2.1. Xenograft Models
Xenograft models have been widely used in cancer research, and can be established either by
direct impla t of tu or tissue fragments o by injection of liver tumor ell lines into recipient mice.
Most plantat on stud es in HCC are pe formed with a subcuta eous x nograft model, in which
human HCC ce ls are implanted subcutaneously (usually in the flanks) into immun deficient mice,
including nude mice, severe combi ed immune deficient (SCID) ice, or non-obese diabetic-severe
combined immunodeficiency diseas (NOD/SCID) mice [22]. For example, Fang et al. inject d HCC
cells stably expre sing miR-124 into the flanks of ude mice to evaluate the potenti l role of miR-124 in
the athogenesi of HCC. With the ectopic overexpressi n of miR-124, the tumor sizes and th number
of intrahepatic and pulmonary m astatic nodules wer significantly decreased, which may have be n
associated with two miR-124 target genes (ROCK2 and EZH2) [23]. Besides miR-124, miR-151 and the
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miR-200 family have also been shown to be downregulated in subcutaneous xenograft models of HCC,
and to negatively regulate different components of the RHO/RHO-associated protein kinase (ROCK)
pathway to inhibit cancer cell invasion and metastasis [28,70]. As cancer stem cells play important
roles in the progression of HCC growth, Meng et al. used SCID mice with subcutaneously injection
of human hepatocellular cancer stem cells (HSCs) to study the functional role of miRNAs in cancer
stem cells. The authors described that inhibition of Twist/miR-181 led to reduced HSCs invasion and
metastasis, whereas silencing of IL-6/let-7 increases the chemosensitivity of HSCs to sorafenib and
doxorubincin [24]. In addition, microRNA deregulation is not only limited to HCC, but can also be
found in the other primary source of liver cancer, cholangiocarcinoma [71]. Han et al. conducted a
circadian rhythm study in CCA by subcutaneous injection of CCA cells (stably transfected with Per1)
into nude mice. Per1 is a key circadian clock gene that is regulated by miR-34a. miR-34a-dependent
overexpression of Per1 reduced tumorigenesis of CCA and the expression of other clock-controlled
genes [72]. Another CCA study evaluated the effect of a miR-24 inhibitor in a xenograft mice model
subcutaneously injected with the inhibitor-transfected CCA cells. Knocking down miR-24 negatively
regulated menin expression and decreased CCA cell proliferation, migration, and angiogenesis [73].
Besides the subcutaneous xenograft models, orthotopic implantation of tumor cells or tumor
tissue fragments has also been widely used to study liver cancer. Wong et al. used this approach to
evaluate the role of miR-139 in HCC metastasis. miR-139-expressing HCC cells were first injected into
nude mice to induce development of subcutaneous tumors. Cubes of the tumors (1 mm3) were cut
and orthotopically implanted in the left hepatic lobe of the nude mice. Overexpression of miR-139
suppressed metastasis and progression of HCC by down-regulating ROCK2 [29]. In addition, the other
common approach to orthotopic implantation is to suspend tumor cells in medium containing 50%
Matrigel and directly inject the Matrigel into the liver of the mouse [74]. miR-130b was shown to
promote cancer stemness properties by enhancing chemoresistance, tumorigenicity, and self-renewal
in orthotopic xenograft SCID mice [32]. Furthermore, recent findings have defined a role for miR-21 in
patient-derived organoids (PDOs). Lampis et al. created organoids from patient biopsies to determine
their mutations and architecture. Utilizing both in vivo and in vitro systems, the researchers found an
inverse correlation with the HSP90 inhibitors and the baseline levels of miR-21. miR21 appeared to
act through the HSP40 family member B5, and the transgenic expression of this molecule in CCA cell
lines reintroduced HSP90 inhibition sensitivity. This data provided insight into the miR21-specific
weakness in CCA, and proof-of-concept for the creation of organoids from patient biopsies in order to
provide more specificity in patient treatments in cholangiocarcinoma [33].
2.2. Chemical-Based Models
Diethylnitrosamine (DEN) is a carcinogenic compound which is frequently used to experimentally
induce liver fibrosis and/or HCC in animals. The incidence of DEN-induced HCC is determined,
at least in part, by the strain. C3H and B6C3F1 mice are more likely to develop HCC compared to
C57BL mice [34]. Recent studies have demonstrated miR-221 to be an oncogenic miRNA which plays
an important role in the progression of HCC. For example, miR-221 overexpression is associated
with sorafenib resistance in a DEN-induced HCC rat model, presumably by modulating caspase 3
expression and cellular apoptosis [40]. In another study, treatment with an antisense 2-O-methyl
oligoribonucleotide targeting miR-221 reduced tumor growth in miR-221tg-DEN-induced HCC mouse
models [41]. In addition, Wu et al. explored the concurrent increase of liver progenitor cells (LPCs) and
transforming growth factor-β (TGF-β) in DEN-induced rat hepatocarcinogenesis. They demonstrated
that TGF-β-induced Akt activation and LPC transformation was mediated by miR-216a-modulated
PTEN suppression [35].
Carbon tetrachloride (CCl4) is another hepatotoxin widely used to induce hepatocarcinogenesis in
rodent animals. In a study with 14 week CCl4 treatment, anti-miR-221 oligonucleotides or miR-199a-3p
mimics prevented HCC progression through the control of multiple cancer-associated molecular
pathways, which included PI3K–AKT, WNT-β-catenin, cell cycle, invasion, and motility. However,
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there were no apparent effects on liver fibrosis and cirrhosis, which was suggested by the similar
expression of α-SMA between treatment groups [46]. miRNA profiling analysis from liver tissues
treated with CCl4 or corn oil for 10 weeks showed that hepatic expression of miR-378 family members
(miR-378a-3p, miR-378b, and miR-378d) was decreased in CCl4-treated mice compared with the control
group, which was inversely correlated with the Hedgehog target genes, Gli2, and Gli3 in tumor and
non-tumor tissues [47]. Interestingly, Marrone et al. evaluated the role of miRNAs in the pathogenesis
of hepatocarcinogenesis in male B6C3F1/J mice treated with DEN or CCl4 alone, or a combination of
DEN and CCl4. Different tumor incidences were observed in the following order: DEN < CCl4 < DEN
+ CCl4 [48].
2.3. Genetically Modified Models
Hepatitis B virus (HBV) is a well-recognized risk factor for HCC. Many types of transgenic mice
harboring hepatitis B virus X (HBx) protein and hepatitis B virus surface antigen (HBsAg) have been
generated. Wang et al. generated HBx and HBsAg knockin transgenic mice by integrating these two
genes into the same p21 locus. Both male and female HBx transgenic mice developed HCC after
the age of 18 months, whereas only male p21–HBsAg transgenic mice between the ages of 15 and
24 months developed HCCs, suggesting that men might be more susceptible to HBV-induced HCC
than women [49]. Using the same p21–HBx transgenic mice, Zhang et al. showed that local liver
metastasis and distant lung metastasis were significantly inhibited by blocking miR-143. Upregulation
of miR-143 expression, transcribed by NF-kB, promotes cancer cell invasion/migration and tumor
metastasis by repression of FNDC3B expression [75]. In addition, Huang et al. showed that miR-152
was downregulated in the livers of HBx transgenic mice. Downregulation of miR-152 led to enhanced
DNA methylation with upregulation of DNMT1, which further promoted HCC development [58].
Autophagy pathway was suppressed and inversely correlated with miR-224 expression in liver tumors
of HBx transgenic mice [76].
Hepatitis C virus (HCV) is another major cause of HCC worldwide. Transgenic mice containing
the complete core gen of HCV were generated by Koike et al. to study the role of HCV core
protein in HCC [50]. Surprisingly, no study has been conducted to examine the role of miRNAs
in HCV-induced-HCC transgenic models. In a HCV infection-induced mice model, miR-155 has
been identified to promote cell proliferation and HCC tumor growth by increasing Wnt/β-catenin
signaling [51].
Multidrug resistance-associated protein 2 (Mdr2) knockout mice have been extensively studied
over the decades, as they provided a model for studying cholestasis, biliary fibrosis, and hepatic
carcinogenesis. Livers of 3 month old Mdr2−/−mice had characteristic portal inflammation and bridging
fibrosis, which was followed by hepatocarcinogenesis at 15 months with nearly 100% efficiency [52].
Wu et al. showed that miR-200b expression was increased in Mdr2−/− mice and decreased in Mdr2−/−
mice subjected to dark exposure or melatonin treatment. Inhibition of miR-200b in Mdr2−/− suppressed
biliary proliferation, liver fibrosis, and angiogenesis [55]. In addition, as extracellular vesicles (EVs)
containing miRNAs can play important roles in various liver diseases, liver-stem-cell-derived EVs
(LSCEVs) and human-hepatocyte-derived EVs (HHEVs) were injected into Mdr2−/− mice to evaluate
miRNA profiling and their downstream target genes [56]. Compared to HHEVs, LSCEV-injected mice
showed increased levels of several miRNAs, including let-7a, let-7b, and miR-25. LSCEVs reduced
ductular reaction and biliary fibrosis in Mdr2−/− mice through let-7-dependent reduction of Lin28a,
Lin28b, IL-13, NF-κB, and NR1H4, and enhancement of FoxA2 [57].
Tetracycline-controlled systems have been widely used for temporal control over genetic changes.
Shachaf et al. crossed TRE–myc11 mice with a transgenic line, LAP–tTA10, where the liver activator
protein (LAP) promoter drives expression of the tetracycline trans-activating protein (tTA) in liver cells.
In this tet-o-myc mouse model, overexpression of myc in adult mice can reproducibly induce HCC
(PMID: 15475948). Using the same tet-o-myc transgenic mouse model, Kota et al. showed that miR-26a
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could specifically reduce cancer cell proliferation, promote tumor-specific apoptosis, and suppress
hepatocarcinogenesis [36].
Genetic depletion of specific miRNAs is another animal model commonly used to study HCC.
Hsu et al. evaluated the biological function of miR-122 through the generation and characterization
of mice with liver-specific (LKO) and germline (KO) deletion of this miRNA locus [59]. Although a
tumor suppressor role for miR-122 has previously been proposed based on in vitro studies and human
HCC samples, these findings provided the first in vivo evidence that loss of miR122 is sufficient to
initiate highly penetrant HCC development. They demonstrated that chronic loss of miR-122 caused
steatohepatitis and altered liver function that eventually led to HCC [59]. Using the same miR-122
knockout mouse model, Valdmanis et al. observed that depletion of miR-122 increased miR-122 mRNA
target expression and reduced the targets of other microRNAs, such as mRNA targets of let-7 and
miR-21 (Nr6a1, Pdcd4, Srsf7, and Stag2), suggesting that when one common miRNA is diminished,
other microRNAs would utilize the newly available miRNA machinery to exert a greater repressive
effect on their targets [77]. In addition, miR-148 deficiency mice significantly enhanced DEN-induced
hepatocarcinogenesis through increased lipid metabolic disorders in mice, suggesting miR-148a as a
potential therapeutic target for the regulation of hepatocarcinogenesis [25].
2.4. Other Models
Besides rodent animal models, miRNA research related to liver cancer has also been performed in
mammalian animals. One recent study designed and validated a platform for ultrasound-mediated
delivery of anticancer miRNA-loaded nanoparticles to pig liver and kidney [37]. In order to achieve
controlled and sustained release of miRNAs into tumor cells, antisense-miR-21 and antisense-miR-10b
have been encapsulated into nanoparticles and delivered guided by focused ultrasound in a noninvasive
way. Compared to untreated control regions, miRNA expression increased 1.9- to 3.7-fold with the
treatment of ultrasound, suggesting that this novel platform has therapeutic potential to improve the
delivery efficiency of miRNA to target regions in liver and other organs in large animal models.
3. Small Interfering RNAs
Unlike microRNAs, small interfering RNAs are exogenous to the cell and defend the integrity
of the organism’s genome. Beginning as long double-stranded RNAs, Dicer chops them into smaller
nucleotides with overhanging ends. These, when removed from their latent strand, can then go on
to silence target messenger RNA [5]. siRNAs not only work within the cell to silence the mRNA
before it its message can be translated into protein (Figure 1B), they also provide an extremely useful
genetic tool for scientists to manipulate pathways, thus determining the benefits and consequences of
such manipulation.
3.1. Xenograft Models
Due to the occurrence of controlled and rapid cell growth common to cancers, the pathways that
regulate the cell cycle offer themselves as attractive targets in research. CDC25 phosphatases are one
such target. CDC25B has been shown to be overexpressed in patient populations with hepatocellular
carcinoma, and this is frequently associated with poor prognosis. Additionally, research has shown that
CDC25B promotes cellular migration and invasion in HCC. Using a xenograft mouse model and siRNA
oligos designed to deplete the CDC25B expression in Hep3B and Hep40 HCC cell lines, researchers then
observed the growth and invasion over a 4 day time period. A group of 4 to 6 week old nude mice were
injected with transfected cells every 2 days, and growth curves and tumor dimensions were plotted
after a 50 day incubation period. Significance between the siRNA22–CDC25B group and the RNAiMAX
was achieved by day 7, with P falling below 0.01 from day 15 onwards. In vitro data further supported
these findings by inhibiting HCC cellular invasion and migration in the CDC25B-siRNA-treated cells.
Altogether, these data support the rationale for specific small molecular inhibitors of CDC25B [38].
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3.2. Chemical-Based Models
However, targeting the cell cycle of hepatocytes is not without complications, as this affects the
overall health and regenerative ability of the liver. Exciting new data have been reported using siRNAs
against ANLN, a cytoskeletal protein that is part of the scaffolding complex and participates in the
regulation of cytokinesis and tumorigenesis. Human data showed an increase in ANLN mRNA in
HCC patient samples when compared to the surrounding healthy liver tissue. Using models of both
carbon tetrachloride and diethylnitrosamine, Zhang et al. injected ANLN knockdown H2.35 liver
cells (FRG mice) or siRNA into LAP–MYC mice to demonstrate the role ANLN plays in survival and
regeneration [75].
3.3. Genetically Modified Models
The researchers also developed mice with transgenes for siRNA against the mRNA of ANLN to
determine the level of tumorigenesis in both DEN and CCl4 HCC models. All experimental models
of hepatocellular carcinoma showed an overall decrease in the presence and size of liver tumors in
both DEN- and CCl4-induced liver damage. However, despite the reduction in the tumors’ ability
to grow, the hepatocytes did not lose their regenerative abilities and there was no difference in
liver-to-body-weight ratios or increases in aspartase or alanine aminotransferase when compared to
their control counterparts. Altogether, these data offer promising targets for treatments while taking
into consideration the surgical resection many patients undergo [78].
Tumor suppressor protein, p53, plays a critical role in cell cycle regulation, differentiation,
and apoptosis. One regulator of p53 is E3 ubiquitin ligase MDM2. This gene is often over-expressed
in human tumors, and regulators of MDM2 may provide valuable targets in the fight against liver
cancer. Using the genetically modified KLF+/− and KLF+/+ mouse models exposed to the chemical
carcinogen DEN, Tarocchi et al. studied the impact on KLF6 loss and resultant tumor formations.
Upon comparison of the tumor to liver surface ratio, the homozygous KLF animals had a dramatic
decrease in the overall percentage when compared to their heterozygous KLF animal counterparts.
By 9 months of age, the heterozygous animals had nearly twice the number of macro- and microscopic
lesions. These data correlated with an increase in MDM2 and a corresponding decrease in the presence
of p53. These findings provide additional information about the molecular abnormalities in HCC [30].
4. PIWI RNAs
Unlike long noncoding RNA‘s, PIWI-interacting RNAs are a class of silencing RNA molecules
that are a mere 21–35 nucleotides in length. Their primary job is to guide PIWI proteins to methylate
DNA and cleave target DNA. Through these mechanisms they are able to fight viral infections and
regulate gene expression (Figure 1D), and they are most active in germ cell lines and cancer cells [31].
Due to the fact the PIWI RNAs have not enjoyed the extensive amount of research some of their
noncoding counterparts have, they offer an opportunity for novel discoveries and pathway mapping
in the ongoing fight against liver cancer.
4.1. Chemical-Based Models
Although this research area is new, recent data has shown a role for piR-823 in the upregulation of
TGF-β1 during liver fibrosis. Utilizing the carbon tetrachloride mouse model of liver fibrosis, in addition
to bile duct ligation (BDL), the researchers isolated the primary HSCs and collected total livers. Not
only did the researchers show a correlation between piR-823 and HSC activation in both fibrotic models,
they also presented data to suggest that piR-823 not only activated HSCs, its increased synthesis
was also the result of activated HSCs, creating a vicious cycle. In addition to these observations,
the researchers also noted an increase in TGF-β1 in the HSCs treated with a piR-823 mimic. Providing
a piR-823 antogomir reduced the TGF-β1 levels further, supporting a role for this PIWI RNA in the
progression of liver cancer [42].
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4.2. Other Models
Often, the only treatment option for liver cancer is surgical resection. Research using the partial
hepatectomy (PH) rat model has described a role for PIWI RNA in the proliferative response the
liver undergoes following PH. First, the researchers determined if known piRNAs were present in
normal rat liver tissue. The researchers found that around 1% of the small RNA molecules could
be identified as piRNAs. Furthermore, the activity of several of the PIWIs was most prevalent at 24
and 48 hours, with a cessation at 168 hours post PH, corresponding with DNA replication and the
activation of the cell cycle [43]. In corroboration of the aforementioned research, the research group of
Dr Lv in Hangzhou, China, identified four novel piRNAs after performing partial hepatectomy on
white spotted bamboo sharks. A one-third PH was performed on the right side of the liver, the sharks
were recovered and continuously fed, and then an additional section was resected 3 hours later to
look for upregulation of known and novel piRNAs. The researchers were able to identify six known
and four novel piRNAs in normal liver tissue. Using a GO and KEGG pathway analysis, they were
able to speculate that pi-1738 has a role in liver regeneration and pi-6084 regulates development and
immune processes. These findings may provide therapeutic pathways and further understanding into
the regenerative properties of the liver [44].
5. Small Nucleolar RNAs
Another group of small non-coding RNA, shown to play a key role in the pathogenesis of
hepatocellular carcinoma, are the small nucleolar RNAs (Figure 1E). These RNAs are 60–300 nucleotides
in length and can be divided into two major classes, the H + ACA snoRNAs and the C + D snoRNAs.
They serve primarily to guide RNAs through post-translational synthesis, working in conjunction with
additional proteins to form snoRNPs [60].
Xenograft Models
Despite their role in methylation and post-translational synthesis, evidence has also emerged that
describes a role for snoRNAs in human malignancies. SNORD50A and -B are often deleted in various
cancers, while SNORA42 is often overexpressed in colorectal and lung cancers. Like SNORA42, ACA11
is also overexpressed in colorectal cancer but lacked a definitive role is HCC. After demonstrating that
ACA11 was highly expressed in HCC tissue when compared to surrounding non-tumor liver tissue,
the researchers utilized male BALB/c nude mice to inject stably transfected ACA11-knocked-down
HCCLM9 cells into the animals’ right flank. Huh7 cells overexpressing ACA11 were injected into the
armpits and tissues were collected at 5 weeks. Overexpression of ACA11 significantly increased tumor
weight and growth when compared to the control tumors. In the knockdown cells the tumor weights
were lower and there was a significant decrease in the Ki67+ hepatocyte nuclei compared to controls.
The researchers then postulated that ACA11 was acting upon the PI3K/AKT pathway. Subsequent
inhibition of this pathway reduced the stimulatory effects and the researchers concluded that there is
biological significance of ACA11 in HCC, and that further research may provide therapeutic targets [79].
However, the intricacies of cancer often mean that a single molecule, an individual target, or a specific
pathway are a single strand in a complex web of pathogenesis. Additional research into the PI3K/AKT
pathway yielded yet another snoRNA, SNORD126. Data from a microarray showed SNORD126 up- or
downregulated a total of 500 separate genes. Due to the microarray results highlighting a link between
SNORD126 and upstream regulators of PI3K, and the well-established role of dysregulation of the
PI3K/AKT pathway in cancer progression, the researchers focused their attention there. Female nude
mice were inoculated with either Huh-7 or SW480 SNORD126-expressing cells, or EGFP-expressing
cells. These cell lines were chosen due to their low endogenous SNORD126 levels. Overexpression of
SNORD126 increased levels of upstream receptors in the PI3K pathway, including FGFR2 and LPAR1.
Chemo-resistance was inferred by overexpression of SNORD126. Subsequently, downregulation
decreased cell growth, suggesting a potential therapeutic pathway for cancer treatment [39].
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6. Long Noncoding RNAs
One novel area of interest in the progression of liver cancer is long non-coding RNAs (lncRNA).
lncRNAs are RNAs that comprise more than 200 nucleotides. Within the human genome, there may
be in excess of 15,000 lncRNA and, similarly to mRNAs, their expression is highly regulated through
transcription factors and methylated lysines [80]. Some predominant roles these lncRNAs play in liver
cancer progression involve the renewal of the stem cells, cancer cell proliferation, communication,
and even metastases (Figure 1C).
6.1. Xenograft Models
Recent studies have indicated a clear role for lncRNA is the progression of liver cancer through
the upregulation of lncARSR. In a tumor model utilizing NOC–SCID mice and hepatoma cells, serially
diluted and mixed with either si-lncARSR or si-NC, there was a significant reduction in the number
of tumors and an overall decrease in the cancer cell markers CD133+ and EpCAM [17]. Additionally,
inhibition of lncARSR impaired STAT3 activity, which has been previously shown to be an active
participant in tumorigenesis [81]. Additional studies analyzing human samples and including the
manipulation of another long noncoding RNA, DILC, supported the previous researchers′ assertion
that STAT3 was involved in the negative regulation of hepatocellular carcinoma. However, the pathway
targeted by the lncRNA DILC is specific to the IL-6 promoter region, and a subsequent knockdown
of lncDILC inversely affected the amount of EpCAM and CD24. NOD–SCID mice inoculated with
the hepatoma cells isolated from mirDILC spheroids or mirCtrl spheroids had significant increases in
both weight and volume. These findings were further validated by patient findings that correlated low
levels of lncDILC expression with early recurrence and high mortality [53].
6.2. Chemical-Based Models
NOC–SCID mice are not the only animal models that have been shown to implicate a role for
lncRNA in liver cancer progression. Liver fibrosis induced by carbon tetrachloride (CCl4) has been
reported to be a result of dysregulation in multiple long non-coding RNA′s such as lncRNA-COX-2.
Research utilizing the CCl4 mouse model of liver fibrosis at 2 and 3 months showed an upregulation in
lncRNA-COX-2 in cirrhotic areas of liver tissue compared to the control group. However, despite a
significant increase in the CCl4 groups over the control, there was no difference noted between the
2 and 3 month CCl4 groups compared to one another [54]. COX-2 has previously been implicated
in both the growth of tumors and the evasion of the immune system, and this research supported a
significant correlation with the RNA expression of COX-2 and the level of liver fibrosis. These findings
offer a therapeutic pathway to be explored. Another therapeutic pathway recently discovered in the
carbon tetrachloride mouse model that offers promise in the progression of liver disease is the lncRNA
nuclear paraspeckle assembly transcript 1 (NEAT1) discovered in primary mouse hepatic stellate cells
(HSCs). In both the in vitro and in vivo models, there was a consistent and continuous increase in the
relative expression of NEAT1. Adenoviral vectors against NEAT1 significantly decreased the presence
of collagen I fibers in liver tissue, among other markers such as KLF6. Regulatory microRNA-122
was found to inversely affect the expression of NEAT1, with significant increases occurring with the
introduction of a miR-122 inhibitor [82]. The rat model CCl4 yielded similar results with regards
to lncRNA-GAS5 and its interaction with miR-23a through the PTEN/P13K/Akt pathway. Building
upon their previous research implicating the upregulation of miR-23a and poor patient prognosis [5],
they then focused on the role of lncRNA-GAS5. lncRNA-GAS5 was identified through bioinformatics
software and further confirmed using a luciferase vector. These promising data showed that the direct
interaction between miR-23a and lncRNA-GAS5 was an inverse relationship, with the result being an
alleviation of hepatic fibrosis and reduction in the activation of HSCs [45].
Recent research using the diethylnitrosamine (DEN)-prompted HCC rat model evaluated a role
for the lncRNA-ecCEBPA and -UCA1. lncRNA-UCA1 has been previously implicated in various
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cancers [11,44,45] including gastric, lung, and prostate. It has also shown to increase cancers’ resistance
to chemotherapeutics [83]. Along the lines of similar studies, UCA1 was overexpressed in the DEN
cancer model, with a transcription level increase of 650% compared to controls. In addition to UCA1,
the lncRNA-ecCEBPA gene was also upregulated in the DEN-treated animals. These levels were
decreased by treatment with S-adenosyl methionine (SAM) via the inhibition of the P13K and Akt
signaling pathway [84].
6.3. Genetically Modified Models
The presence or overexpression of previously identified long noncoding RNAs in liver cancer
do not necessarily yield the desired targets for therapeutics, but may offer biomarkers for liver
carcinogenesis. A recent study supported this idea through the study of non-coding nuclear-enriched
abundant transcript 2 (NEAT2), commonly known as Malat1. Previous studies have shown that Malat1,
expressed in high levels, correlates with poor prognosis in various cancers, including liver cancer [26].
Based upon this, and similar studies, the researchers generated a Malat1 knockout mouse through
the use of a gene trapping technique. However, despite the decrease in hepatic mRNA levels of Ki67,
TERT, Foxo3 and others, the overall tumorigenicity did not change when compared to the wild type
controls [27]. Another popular model of liver disease is the multidrug resistant 2 knockout mouse
model of hepatocellular carcinoma. The benefit to the MDR2 KO model is the dysregulation of several
pathways that create a disease state that mimics the familial intrahepatic cholestasis found in humans.
As a result, these animals provide a link between inflammation and HCC [85]. MDR2 KO models
may also be used to study the gender variations of cholestatic injuries. One such study explored the
pronounced hepatobiliary progression of females over age-matched males through the exploration of
lncRNA-H19. lncRNA-H19 is an estrogen-targeted gene, maternally expressed and present in both
murine and human cirrhotic livers. Data revealed that H19 levels were very low in the FVB control mice,
with no significance noted between the male and female animals. However, the same time point in the
disease model showed a 200-fold increase in the females’ expression of lncRNA-H19. Furthermore,
the upregulation of H19 was a result of the taurocholic acid activation of S1PR2, which was found to
also be upregulated in human PSC patients, especially females. These very important data provide a
focal point for further research into the gender disparity between severity of hepatobiliary injuries in
men and women [86].
7. Conclusions
Currently, there are numerous well-established animal models in use in the study of liver cancer.
These cover a wide range of targets and pathways, from genetically engineered knockin or knockout
mouse models utilized to elucidate specific molecular roles, to bamboo sharks used in the study of
the immune processes of the liver. Recent scientific discoveries in the area of noncoding RNAs have
created a landscape of opportunity in pathway modification and therapeutic targeting. Since the
discovery of the first miRNA twenty-six years ago, we have greatly increased our understanding of
various genes’ functions and regulation within the cell. However, even though our foundation is solid,
there are still gaping holes in our knowledge. There are numerous opportunities for progress to be
made, particularly in the lesser-studied noncoding RNAs such as PIWI-RNAs and small nucleolar
RNAs. In addition, the only well covered small RNA group in terms of the available animal models is
the miRNAs. In conclusion, the roles noncoding RNAs play in the regulation of cellular apoptosis,
activation, and regeneration in the progression of liver cancer, and the animal models used to study
and elucidate these pathways, provide vast information for the potential development of therapeutic
targets of hepatocellular carcinoma.
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